Comparative Pharmacology
Head-to-head clinical analysis: MPI INDIUM DTPA IN 111 versus XENON XE 133 V S S.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MPI INDIUM DTPA IN 111 versus XENON XE 133 V S S.
MPI INDIUM DTPA IN 111 vs XENON XE 133-V.S.S.
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Indium In-111 DTPA is a radiopharmaceutical that emits gamma radiation, used for imaging. DTPA chelates indium-111 and, after administration, distributes in the extracellular fluid and is cleared by glomerular filtration, allowing cisternography and renal imaging.
Xenon Xe-133 is a radioactive gas that emits beta and gamma radiation. It distributes to the lungs and is used for ventilation-perfusion imaging. Its mechanism is based on regional distribution in the lungs, reflecting ventilation. It does not have pharmacological activity.
Adult: 18.5 MBq (0.5 mCi) administered intravenously as a single dose for renal imaging.
5-10 mCi (185-370 MBq) inhaled as a single dose for pulmonary ventilation imaging.
None Documented
None Documented
Terminal half-life: 2.5-4.0 hours (plasma); prolonged in renal impairment.
Terminal elimination half-life of approximately 3.5 minutes, corresponding to rapid washout from lungs following cessation of inhalation.
Renal: 90% within 24 hours via glomerular filtration; minimal biliary/fecal (<5%).
Eliminated almost entirely via exhalation through the lungs (>95%); negligible renal or biliary/fecal excretion.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical